USA - NASDAQ:CALA - US13089P5070 - Common Stock
Taking everything into account, CALA scores 3 out of 10 in our fundamental rating. CALA was compared to 534 industry peers in the Biotechnology industry. While CALA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CALA is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.42 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.76 | ||
| Quick Ratio | 3.76 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.3651
-0.04 (-10.95%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.07 | ||
| P/tB | 0.07 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.43% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.76 | ||
| Quick Ratio | 3.76 | ||
| Altman-Z | -27.42 |
ChartMill assigns a fundamental rating of 3 / 10 to CALA.
ChartMill assigns a valuation rating of 3 / 10 to CALITHERA BIOSCIENCES INC (CALA). This can be considered as Overvalued.
CALITHERA BIOSCIENCES INC (CALA) has a profitability rating of 0 / 10.
The financial health rating of CALITHERA BIOSCIENCES INC (CALA) is 2 / 10.